The Journal of dermatological treatment · 2025
Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Jing, Jing Ming, Liu Ming, Fang Liya, Yang Luan, Qiao Guizhi
Аннотация
OBJECTIVES: To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.
METHODS: We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.
RESULTS: Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.
CONCLUSIONS: Apremilast may be a safe and effective option for refractory PLEVA.
METHODS: We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.
RESULTS: Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.
CONCLUSIONS: Apremilast may be a safe and effective option for refractory PLEVA.